Astrana Health, Inc. posted a remarkable rebound in revenue to over $519 million in 2025, driven largely by acquisition-related growth, despite operating income retreating modestly. The company maintains a strong liquidity position with $429.5 million in cash and an increased buyback authorization now set at $100 million. Material weaknesses in financial controls related to acquisition accounting pose ongoing risk. Investors should monitor upcoming filings for resolution progress and clarity on the business model as disclosures remain limited.